It's not common for a company to sue its largest shareholder. But Esperion Therapeutics Inc. finds itself in that position after revealing late Monday its litigation against Scott Sacane and hedge funds he manages. Just four weeks ago, Esperion discovered that Sacane and his related entities had acquired about a third of its outstanding shares. (BioWorld Today)

It's not common for a company to sue its largest shareholder. But Esperion Therapeutics Inc. finds itself in that position after revealing late Monday its litigation against Scott Sacane and hedge funds he manages. Just four weeks ago, Esperion discovered that Sacane and his related entities had acquired about a third of its outstanding shares. (BioWorld Today)

Coley Pharmaceutical Group Inc. secured $35 million in private financing to fund further development of its clinical pipeline. (BioWorld Today)

Coley Pharmaceutical Group Inc. secured $35 million in private financing to fund further development of its clinical pipeline. (BioWorld Today)

Looking to bolster cash reserves as it continues late-stage development of its lead products, Pain Therapeutics Inc. registered with the SEC for a follow-on stock offering that could raise about $51.6 million. (BioWorld Today)

Looking to bolster cash reserves as it continues late-stage development of its lead products, Pain Therapeutics Inc. registered with the SEC for a follow-on stock offering that could raise about $51.6 million. (BioWorld Today)

Three biotech companies recently have filed for initial public offerings in what appears to be a developing trend. (BioWorld Today)